Search

Your search keyword '"Bonomi L"' showing total 353 results
Start Over Author "Bonomi L"
353 results on '"Bonomi L"'

1. Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach

Author

Ceresoli, G, Rossi, G, Agustoni, F, Bonomi, L, Borghetti, P, Bulotta, A, Casartelli, C, Cerea, G, Colonese, F, del Signore, E, Finocchiaro, G, Gianoncelli, L, Grisanti, S, Maiolani, M, Pagni, F, Proto, C, Rijavec, E, Vittimberga, I, Arcangeli, S, Filippi, A, Ceresoli, Giovanni Luca, Rossi, Giulio, Agustoni, Francesco, Bonomi, Lucia, Borghetti, Paolo, Bulotta, Alessandra, Casartelli, Clelia, Cerea, Giulio, Colonese, Francesca, del Signore, Ester, Finocchiaro, Giovanna, Gianoncelli, Letizia, Grisanti, Salvatore, Maiolani, Martina, Pagni, Fabio, Proto, Claudia, Rijavec, Erika, Vittimberga, Isabella, Arcangeli, Stefano, Filippi, Andrea Riccardo, Ceresoli, G, Rossi, G, Agustoni, F, Bonomi, L, Borghetti, P, Bulotta, A, Casartelli, C, Cerea, G, Colonese, F, del Signore, E, Finocchiaro, G, Gianoncelli, L, Grisanti, S, Maiolani, M, Pagni, F, Proto, C, Rijavec, E, Vittimberga, I, Arcangeli, S, Filippi, A, Ceresoli, Giovanni Luca, Rossi, Giulio, Agustoni, Francesco, Bonomi, Lucia, Borghetti, Paolo, Bulotta, Alessandra, Casartelli, Clelia, Cerea, Giulio, Colonese, Francesca, del Signore, Ester, Finocchiaro, Giovanna, Gianoncelli, Letizia, Grisanti, Salvatore, Maiolani, Martina, Pagni, Fabio, Proto, Claudia, Rijavec, Erika, Vittimberga, Isabella, Arcangeli, Stefano, and Filippi, Andrea Riccardo

Abstract

Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.

Published
2024

2. EP06.05-06 Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients

Author

Mollica, L., primary, Intagliata, S., additional, Bonomi, L., additional, Ghilardi, L., additional, Morotti, D., additional, Ghirardi, G., additional, Antelmi, E., additional, Gianatti, A., additional, Carioli, G., additional, Muglia, R., additional, Marra, P., additional, Raimondi, F., additional, Ciaravino, G., additional, Di Marco, F., additional, Sironi, S., additional, Tondini, C.A., additional, and Bettini, A.C., additional

Published
2023
Full Text
View/download PDF

4. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases

Author

Lagana, M, Gurizzan, C, Roca, E, Cortinovis, D, Signorelli, D, Pagani, F, Bettini, A, Bonomi, L, Rinaldi, S, Berardi, R, Filetti, M, Giusti, R, Pilotto, S, Milella, M, Intagliata, S, Baggi, A, Cortellini, A, Soto Parra, H, Brighenti, M, Petrelli, F, Bennati, C, Bidoli, P, Garassino, M, Berruti, A, Lagana M., Gurizzan C., Roca E., Cortinovis D., Signorelli D., Pagani F., Bettini A., Bonomi L., Rinaldi S., Berardi R., Filetti M., Giusti R., Pilotto S., Milella M., Intagliata S., Baggi A., Cortellini A., Soto Parra H., Brighenti M., Petrelli F., Bennati C., Bidoli P., Garassino M. C., Berruti A., Lagana, M, Gurizzan, C, Roca, E, Cortinovis, D, Signorelli, D, Pagani, F, Bettini, A, Bonomi, L, Rinaldi, S, Berardi, R, Filetti, M, Giusti, R, Pilotto, S, Milella, M, Intagliata, S, Baggi, A, Cortellini, A, Soto Parra, H, Brighenti, M, Petrelli, F, Bennati, C, Bidoli, P, Garassino, M, Berruti, A, Lagana M., Gurizzan C., Roca E., Cortinovis D., Signorelli D., Pagani F., Bettini A., Bonomi L., Rinaldi S., Berardi R., Filetti M., Giusti R., Pilotto S., Milella M., Intagliata S., Baggi A., Cortellini A., Soto Parra H., Brighenti M., Petrelli F., Bennati C., Bidoli P., Garassino M. C., and Berruti A.

Abstract

Objectives: The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated with modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated. Materials and Methods: We retrospectively evaluated the data of EGFR mutated NSCLC patients with bone metastases treated with TKIs in 12 Italian centers from 2014 to 2019, with the primary aim to explore type and frequency of SREs. Results: Seventy-seven out of 274 patients enrolled (28%) developed at least one major SRE: 55/274 (20%) bone fractures, 30/274 (11%) spinal cord compression, 5/274 (2%) hypercalcemia. Median time to the onset of SRE was 3.63 months. Nine patients (3%) underwent bone surgery and 150 (55%) radiation therapy on bone. SREs were more frequently observed within the 12 months from TKI start than afterwards (71 vs 29%, p 0.000). Patient Performance Status and liver metastases where independently associated with the risk of developing SREs. Median TKI exposure and overall survival were 11 and 28 months, respectively. Bone resorption inhibitors were associated with a lower risk of death (HR 0.722, 95% CI: 0.504–1.033, p = 0.075) although not statistically significant at multivariate analysis. Conclusion: Bone metastatic NSCLC patients with EGFR mutated disease, treated with EGFR TKIs, have a relatively long survival expectancy and are at high risk to develop SREs. The early SRE occurrence after the TKI start provides the rationale to administer bone resorption inhibitors.

Published
2020

7. 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

Author

Iacovelli, R., Ciccarese, C., Bersanelli, M., Zucali, P.A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., G. fornarini, Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Buti, S., Perrino, M.R.A., Pafumi, S., and Tortora, G.

Published
2023
Full Text
View/download PDF

17. MA 02.05 Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP)

Author

Ardizzoni, A., primary, Bidoli, P., additional, Chiari, R., additional, Bonomi, L., additional, Turci, D., additional, Landi, L., additional, Toschi, L., additional, De Tursi, M., additional, Francini, G., additional, Giordano, M., additional, Alabiso, O., additional, De Censi, A., additional, Livi, L., additional, Berruti, A., additional, Minelli, M., additional, Ricevuto, E., additional, Illiano, A., additional, Puppo, G., additional, Delmonte, A., additional, and Galetta, D., additional

Published
2017
Full Text
View/download PDF

22. The European glaucoma prevention study design and baseline description of the participants

Author

Miglior, S, Zeyen, T, Pfeiffer, N, Cunha-Vaz, J, Linsen, M, Pellicci, L, Janssens, A, Van der Veken, A, Nerinckx, F, Boeyden, V, Detry-Morel, M, Kestelijn, P, Van den Abeele, K, Jacobs, K, Decock, C, Goethals, M, Pourjavan, S, Maris, K, Kersten, I, Vogel, A, Herkel, U, Schwenn, O, Maser-Wahle, M, Funk, J, Schmidt, B, Akbariyeh, N, Burk, R, Thomsen, A, Grehn, F, Marquardt, D, Orzalesi, N, Rossetti, L, Ferrante, M, Mandelli, L, Marini, S, Bagno, S, Bertoni, G, Blini, M, De Molfetta, M, Bonomi, L, Morbio, R, Marraffa, M, Maraini, G, Gandolfi, S, Williams, S, Cimino, L, Dondi, P, Lumbroso, B, Manni, G, Cocco, F, Glorialanza, G, Maria Villani, C, Pocobelli, A, Cesareo, M, Cupo, G, Neuschuler, R, Pernini, C, Catalani, R, Ribeiro, L, Faria, I, Moura Pereira, J, Chingui, S, Duarte, L, Carvalheira, F, Baltar, A, Simao, A, Arede, J, Magalhaes, A, Abrantes, P, Reina, M, Pedro Silva, J, Romano, G, Silva, S, Adamsons, I, Caprioli, J, Torri, V, Poli, D, Nerviani, C, Tinazzi, A, Miglior S., Zeyen T., Pfeiffer N., Cunha-Vaz J., Linsen M. -C., Pellicci L., Janssens A., Van der Veken A., Nerinckx F., Boeyden V., Detry-Morel M., Kestelijn P., Van den Abeele K. V., Jacobs K., Decock C., Goethals M., Pourjavan S., Maris K., Kersten I., Vogel A., Herkel U., Schwenn O., Maser-Wahle M., Funk J., Schmidt B., Akbariyeh N., Burk R., Thomsen A., Grehn F., Marquardt D., Orzalesi N., Rossetti L., Ferrante M., Mandelli L., Marini S., Bagno S., Bertoni G., Blini M., De Molfetta M., Bonomi L., Morbio R., Marraffa M., Maraini G., Gandolfi S., Williams S., Cimino L., Dondi P., Lumbroso B., Manni G., Cocco F., Glorialanza G., Maria Villani C., Pocobelli A., Cesareo M., Cupo G., Neuschuler R., Pernini C., Catalani R., Ribeiro L., Faria I., Moura Pereira J., Chingui S., Duarte L., Carvalheira F., Baltar A., Simao A., Arede J., Magalhaes A., Abrantes P., Reina M., Pedro Silva J., Romano G., Silva S., Adamsons I., Caprioli J., Torri V., Poli D., Nerviani C., Tinazzi A., Miglior, S, Zeyen, T, Pfeiffer, N, Cunha-Vaz, J, Linsen, M, Pellicci, L, Janssens, A, Van der Veken, A, Nerinckx, F, Boeyden, V, Detry-Morel, M, Kestelijn, P, Van den Abeele, K, Jacobs, K, Decock, C, Goethals, M, Pourjavan, S, Maris, K, Kersten, I, Vogel, A, Herkel, U, Schwenn, O, Maser-Wahle, M, Funk, J, Schmidt, B, Akbariyeh, N, Burk, R, Thomsen, A, Grehn, F, Marquardt, D, Orzalesi, N, Rossetti, L, Ferrante, M, Mandelli, L, Marini, S, Bagno, S, Bertoni, G, Blini, M, De Molfetta, M, Bonomi, L, Morbio, R, Marraffa, M, Maraini, G, Gandolfi, S, Williams, S, Cimino, L, Dondi, P, Lumbroso, B, Manni, G, Cocco, F, Glorialanza, G, Maria Villani, C, Pocobelli, A, Cesareo, M, Cupo, G, Neuschuler, R, Pernini, C, Catalani, R, Ribeiro, L, Faria, I, Moura Pereira, J, Chingui, S, Duarte, L, Carvalheira, F, Baltar, A, Simao, A, Arede, J, Magalhaes, A, Abrantes, P, Reina, M, Pedro Silva, J, Romano, G, Silva, S, Adamsons, I, Caprioli, J, Torri, V, Poli, D, Nerviani, C, Tinazzi, A, Miglior S., Zeyen T., Pfeiffer N., Cunha-Vaz J., Linsen M. -C., Pellicci L., Janssens A., Van der Veken A., Nerinckx F., Boeyden V., Detry-Morel M., Kestelijn P., Van den Abeele K. V., Jacobs K., Decock C., Goethals M., Pourjavan S., Maris K., Kersten I., Vogel A., Herkel U., Schwenn O., Maser-Wahle M., Funk J., Schmidt B., Akbariyeh N., Burk R., Thomsen A., Grehn F., Marquardt D., Orzalesi N., Rossetti L., Ferrante M., Mandelli L., Marini S., Bagno S., Bertoni G., Blini M., De Molfetta M., Bonomi L., Morbio R., Marraffa M., Maraini G., Gandolfi S., Williams S., Cimino L., Dondi P., Lumbroso B., Manni G., Cocco F., Glorialanza G., Maria Villani C., Pocobelli A., Cesareo M., Cupo G., Neuschuler R., Pernini C., Catalani R., Ribeiro L., Faria I., Moura Pereira J., Chingui S., Duarte L., Carvalheira F., Baltar A., Simao A., Arede J., Magalhaes A., Abrantes P., Reina M., Pedro Silva J., Romano G., Silva S., Adamsons I., Caprioli J., Torri V., Poli D., Nerviani C., and Tinazzi A.

Abstract

Objectives: The European Glaucoma Prevention Study seeks to evaluate the efficacy of reducing intraocular pressure (IOP), with dorzolamide to prevent or delay patients affected by ocular hypertension from developing primary open-angle glaucoma. Design: Randomized, double-blinded, controlled clinical trial. Participants: Patients (age ≥ 30 years) were enrolled from 18 European centers. The patients fulfilled a series of inclusion criteria including the measurements of IOP (22-29 mmHg), two normal and reliable visual fields (VFs) (on the basis of mean defect and corrected pattern standard deviation/corrected loss of variance of standard 30/11 Humphrey or Octopus perimetry), and normal optic disc as determined by the Optic Disc Reading Center (vertical and horizontal cup-to-disc ratios; asymmetry between the two eyes ≤ 0.4). Intervention: Patients were randomized to the treatment with dorzolamide or a placebo. Main Outcome Measures: End points are VF and/or optic disc changes. A VF change during the follow-up must be confirmed by two further positive tests. Optic disc change is defined by the agreement of two out of three independent observers evaluating optic disc stereo-slides. Results: One thousand seventy-seven subjects were randomized between January 1, 1997 and May 31, 1999. The mean age was 57.03 ± 10.3 years; 54.41% were women and 99.9% were Caucasian. Mean IOP was 23.6 ± 1.6 mmHg in both eyes. Mean visual acuity was 0.97 ± 0.11 in both eyes; mean refraction was 0.23 ± 1.76 diopters in the right eye and 0.18 ± 1.79 diopters in the left eye. Previous use of medication for ocular hypertension was reported by 38.4% of the patients, systemic hypertension by 28.1%, cardiovascular diseases by 12.9%, and diabetes mellitus by 4.7%. The qualifying VFs were normal and reliable according to protocol criteria. Conclusions: The mean IOP of the patients enrolled in the European Glaucoma Prevention Study is consistent with the estimated mean IOP (within the range of 22-29 mmH

Published
2002

23. Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy

Author

Bidoli, P., primary, Chiari, R., additional, Catino, A., additional, Grossi, F., additional, Noberasco, C., additional, Gelsomino, F., additional, Gilli, M., additional, Proto, C., additional, Parra, H.J. Soto, additional, Migliorino, M.R., additional, Bonomi, L., additional, Tassinari, D., additional, Frassoldati, A., additional, Albanese, V., additional, Fadda, G.M., additional, Cognetti, F., additional, de galitiis, F., additional, Finocchiaro, G., additional, and Delmonte, A., additional

Published
2016
Full Text
View/download PDF

24. Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience

Author

Bonomi, M., primary, Bonomi, L., additional, Sauta, M.G., additional, Bettini, A.C., additional, Squadroni, M., additional, Brena, F., additional, Cerchiaro, E., additional, Ripa, C., additional, Salvini, P., additional, Beretta, G.D., additional, Tondini, C., additional, and Ceresoli, G.L., additional

Published
2016
Full Text
View/download PDF

30. Effectiveness of direct egfr mutations research at time of diagnostic biopsy for lung cancer: a single institution outcome research

Author

Ghilardi, L., primary, Massazza, G., additional, Bonomi, L., additional, Ciaravino, G., additional, Michetti, G., additional, Oprandi, B., additional, Lucianetti, A., additional, Candiago, E., additional, Bertuletti, C., additional, Gianatti, A., additional, Tondini, C.A., additional, Labianca, R., additional, and Bettini, A.C., additional

Published
2015
Full Text
View/download PDF

33. Central corneal thickness in the European Glaucoma Prevention Study

Author

Pfeiffer, N, Torri, V, Miglior, S, Zeyen, T, Adamsons, I, Cunha-Vaz, J, Linsen, Mc, Pellicci, L, Janssens, A, van der Veken, A, Nerinckx, F, Boeyden, V, Kestelijn, P, Van den Abeele, K, Jacobs, K, Decock, C, Goethals, M, Pourjavan, S, Maris, K, Kersten, I, Vogel, A, Herkel, U, Schwenn, O, Maser-Wahle, M, Funk, J, Schmidt, B, Akbariyeh, N, Burk, R, Thomsen, A, Grehn, F, Marquardt, D, Orzalesi, N, Rossetti, L, Ferrante, M, Mandelli, L, Bertoni, G, Blini, M, De Molfetta, M, Bonomi, L, Morbio, R, Marraffa, M, Maraini, G, Gandolfi, S, Williams, S, Cimino, L, Dondi, P, Lumbroso, B, Marini, G, Centofanti, M, Cocco, F, Glorialanza, G, Villani, Cm, Pocobelli, A, Cesareo, M, Cupo, G, Neuschuler, R, Pernini, C, Catalani, R, Ribeiro, L, Faria, I, Pereira, Jm, Chingui, S, Duarte, L, Carvalheira, F, Baltar, A, Simao, A, Arede, J, Magalhaes, A, Abrantes, P, Reina, M, Silva, Jp, Romano, G, Silva, S, Floriani, I, Poli, D, Tinazzi, A, Caprioli, J, Wormald, R, Hejil, A, Airaksinen, J, Michaelis, J, Mandelli, La, Bagno, S, Shedden, A, Gottfried, E, Hutzelmann, J, Rusk, C, Reines, S, Spector, R, Hombrey, J, Snyder, H, Gacos, J, Snapinn, S, Getson, A, Amos, J, Serruys, K, Malbecq, W, John, E, Chapman, J, Beck, J, Tessi, C, Rao, N, Bottari, Fp, D'Achille, R, Wilkins, A, Magerl, K, Bauer, C, Derouwaux, C, Cunha, M, Santana, R, Andrade, Lg, Bule, S, Melo, R, Baumont, H, Bonaventura, I, Pfeiffer, N, Torri, V, Miglior, S, and The European Glaucoma Prevention Study, G

Subjects
Adult, Male, Intraocular pressure, medicine.medical_specialty, genetic structures, Settore MED/06 - Oncologia Medica, Glaucoma, ocular hypertension, central corneal thickness, Ocular hypertension, Glaucoma, Thiophenes, Placebo, law.invention, Cornea, Diabetes Complications, Sex Factors, Double-Blind Method, Randomized controlled trial, Dorzolamide, law, Diabetes mellitus, Ophthalmology, medicine, Humans, Intraocular Pressure, Aged, Ultrasonography, Sulfonamides, business.industry, Age Factors, Middle Aged, medicine.disease, eye diseases, Surgery, medicine.anatomical_structure, Female, Ocular Hypertension, sense organs, business, medicine.drug
Abstract

Purpose: To measure central corneal thickness (CCT) within the participants of the European Glaucoma Prevention Study (EGPS). This study was designed to test if lowering intraocular pressure (IOP) by means of dorzolamide is able to prevent or delay conversion from ocular hypertension to glaucoma. Design: Randomized, double-masked, controlled, observational clinical trial. Participants: Eight hundred fifty-four of 1077 ocular hypertensive participants within the EGPS were investigated. Four hundred twenty-nine patients were treated with dorzolamide and 425 patients received placebo. Intervention: Treatment with dorzolamide or placebo (the vehicle of dorzolamide) in 1 or both eyes. Main Outcome Measures: Central corneal thickness as measured by ultrasound pachymetry (DGH-500 Pachette; DGH Technologies, Exton, PA). The CCT measurements were obtained in the morning before measuring IOP. Five measurements were taken from each eye of each patient within 5 minutes of application of anesthetic eye drops. Results: Mean CCT was 572.6±37.4 μm (range, 458.5-695.6 μm). The CCT was higher in younger patients, male patients, and diabetic patients. Mean CCTs for the 429 patients receiving dorzolamide were 574.2±38.48 μm (range, 458.5-695.6 μm) and 571.0±36.21 μm (469.7-690.1 μm) for the 425 patients receiving placebo (P = 0.205). Central corneal thickness did not correlate with refraction, baseline IOP, or systemic hypertension. Conclusion: Central corneal thickness measurements within the EGPS were greater than those reported in other studies of normal eyes without ocular hypertension. Larger CCT measurements correlated with male gender, younger age, and diabetes. © 2007 American Academy of Ophthalmology.

Published
2007

37. Reproducibility of evaluation of optic disc change for glaucoma with stereo optic disc photographs

Author

Miglior, S, Zeyen, T, Pfeiffer, N, Cunha-Vaz, J, Linsen, Mc, Pellicci, L, Janssens, A, van der Veken, A, Nerinckx, F, Boeyden, V, Czupper, M, Wendrix, G, Detry-Morel, M, Kestelyn, P, Van den Abeele, K, Jacobs, K, Decock, C, Goethals, M, Pourjavan, S, Maris, K, Deghislage, C, Kersten, I, Vogel, A, Herkel, U, Schwenn, O, Maser-Wahle, M, Funk, J, Schmidt, B, Akbariyeh, N, Burk, R, Thomsen, A, Grehn, F, Marquardt, D, Orzalesi, N, Rossetti, L, Ferrante, M, Mandelli, L, Marini, S, Bertoni, G, Blini, M, De Molfetta, M, Bonomi, L, Morbio, R, Marraffa, M, Maraini, G, Gandolfi, S, Williams, S, Cimino, L, Dondi, P, Lumbroso, B, Manni, G, Cocco, F, Glorialanza, G, Villani, Cm, Pocobelli, A, Cesareo, M, Cupo, G, Neuschuler, R, Pernini, C, Catalani, R, Ribeiro, L, Faria, I, Pereira, Jm, Chingui, S, Duarte, L, Carvalheira, F, Baltar, A, Simao, A, Arede, J, Magalhaes, A, Abrantes, P, Reina, M, Silva, Jp, Romano, G, Silva, S, Torri, V, Poli, D, Nerviani, C, Tinazzi, A, Floriani, I, Adamsons, I, Caprioli, J, Wormald, R, Heijl, A, Airaksinen, J, Michaelis, J, Shedden, A, Gottfried, E, Hutzelmann, J, Rusk, C, Reines, S, Spector, R, Hombrey, J, Snyder, H, Gacos, J, Snapinn, S, Getson, A, Amos, J, Serruys, K, Malbecq, W, John, E, Chapman, J, Beck, J, Tessi, C, Rao, N, Bottari, Fp, D'Achille, R, Wilkins, A, Bauer, C, Derouwaux, C, Van der Straeten, A, Cunha, M, Santana, R, Andrade, Lg, Bule, S, Melo, R, Baumont, H, and Bonaventura, I

Subjects
medicine.medical_specialty, genetic structures, Optic Disk, Optic disk, Glaucoma, Interobserver reproducibility, Cohen's kappa, Double-Blind Method, Ophthalmology, Optic Nerve Diseases, medicine, Photography, Humans, Observer Variation, Reproducibility, business.industry, Outcome measures, Reproducibility of Results, medicine.disease, eye diseases, Confidence interval, medicine.anatomical_structure, sense organs, business, Optic disc
Abstract

PURPOSE To determine the reproducibility of the assessment for glaucomatous change in serial optic disc stereo-slides. DESIGN Masked interobserver variability study. PARTICIPANTS Serial optic disc stereo-slides from 40 patients. METHODS Three independent ophthalmologists evaluated for change a set of two serial 20 degrees optic disc color stereo-slides of 40 patients. This test set was not from European Glaucoma Prevention Study (EGPS) patients. Each observer performed two evaluations at least 30 days apart and was masked from the temporal sequence of the slides and his or her previous evaluation. Each patient was graded as changed or stable by two-out-of-three agreement. A kappa statistic was used to calculate the intra- and interobserver reproducibility as well as the assignment reproducibility (first consensus versus second consensus). The same procedure was followed to test the reproducibility when another experienced ophthalmologist was added to one of the three reading centers. MAIN OUTCOME MEASURES Reproducibility in evaluating glaucomatous optic disc change. RESULTS The intraobserver reproducibility (95% confidence interval [CI]) in the evaluation of change ranged between 0.79 (0.45-1.14) and 1.00 (0.69-1.31). The interobserver reproducibility (95% CI) in the evaluation of change ranged between 0.45 (0.15-0.75) and 0.75 (0.44-1.06). The assignment reproducibility (first consensus versus second consensus in the evaluation of change) between the senior EGPS readers was 0.94 (0.63-1.25). The assignment reproducibility when another experienced ophthalmologist replaced one of the readers was 0.94 (0.63-1.25). CONCLUSIONS The assignment reproducibility of three expert readers looking for glaucomatous change in serial optic disc stereo-slides was excellent. It remained so when one of the three experts was replaced by another experienced reader.

Published
2003

39. Egna-Neumarkt glaucoma study

Author

Bonomi, L., Marchini, Giorgio, Marraffa, M., Bernardi, P., De Franco, I., Perfetti, S., and Varotto, A.

Subjects
n/a
Published
2001

Catalog

Books, media, physical & digital resources
See catalog results